Fifteen Years of OCT Innovation: From Signal Processing to Surgical Robots

Optical Coherence Tomography has transitioned over approximately 15 years of continuous patent filings — from 2010 to early 2026 — from a primarily diagnostic tool into a real-time intraoperative guidance platform. The foundational mechanism of low-coherence interferometry, in which a broadband or swept light source is split into sample and reference arms, is common across nearly all retrieved patents; differentiation has shifted to how spectral information is decoded, how scanning is implemented, and how output data is processed and displayed.

The innovation timeline breaks into three distinct phases. The early foundation period (2010–2015) is dominated by core signal-processing and optical architecture patents, including Zhejiang University’s wide-spectrum spectral-domain detection method using spatiotemporal beam splitting (filed 2010–2011, CN) and the University of Texas System’s forward-imaging fiber-based OCT probe (2010, JP). Carl Zeiss Meditec established foundational wide-field retinal OCT stitching approaches in 2015 (CN), while Doheny Eye Institute contributed OCT-based ophthalmic testing systems in 2011 (EP, US) that prefigured self-administered patient testing.

The mid-stage development period (2016–2021) is characterized by rapid proliferation of intraoperative OCT systems and AI-augmented image processing. Alcon Lensx/Alcon filed SD-OCT-guided cataract surgery patents from 2017 to 2020 (JP), and Novartis/Bioptigen contributed procedural OCT methods from 2016 to 2019 (JP, EP). The Medical University of Vienna’s AI prediction model for OCT tissue analysis appeared across multiple jurisdictions from 2016 (WO) through 2020 (US), representing one of the most geographically distributed single-assignee AI OCT portfolios in the dataset.

The most recent filing window (2022–2026) signals convergence of OCT with robotics, augmented reality, and intraocular lens adjustment. Alcon Inc. filed OCT-guided robotic ophthalmic procedure patents in 2025 (JP) and integrated visualization plus OCT system filings in 2025 (EP). Toward Pi (Beijing) Medical Technology filed intraoperative OCT navigation systems in 2026 (KR), representing the leading edge of the dataset.

Core Engine Architectures: SD-OCT, SS-OCT, and the Race for Speed

Spectral-domain OCT and swept-source OCT represent the dominant acquisition architectures across this dataset, each with distinct performance trade-offs that have driven parallel innovation streams. SD-OCT uses a spectrometer to decode depth information in parallel, while SS-OCT uses a rapidly tuned narrowband laser to encode depth as frequency over time — enabling higher acquisition speeds and longer imaging ranges that make it better suited for intraoperative and wide-field applications.

The University of Kent’s 2018 JP filing introduces master-slave interferometry, which enables parallel coherence gating from positive and negative optical path differences and eliminates the k-space linearization step that traditionally adds computational overhead to SD-OCT pipelines. Zhejiang University’s 2011 CN patent uses cascaded temporal and spatial dispersive elements to achieve high signal-to-noise ratio spectral-domain detection while suppressing field curvature artifacts — a persistent challenge in wide-field retinal imaging.

Thorlabs’ 2022 CN filing on MEMS-tunable VCSEL-driven swept-source OCT demonstrates a significant application expansion: repurposing OCT for high-speed non-contact 3D digitization of engineered objects, replacing mechanical coordinate measurement machine probes with reconfigurable optical probes. This industrial metrology application — documented by IEEE as a growing area for optical sensing — illustrates how OCT’s core speed and depth-resolution advantages translate directly to non-biological precision measurement contexts.

A distinct sub-domain addresses anterior and posterior segment switching. Carl Zeiss Meditec’s 2019 JP filing implements mode-switchable imaging by controlling spectral bandwidth relative to the 1060 nm water absorption window — a wavelength range that penetrates the anterior chamber while also enabling posterior retinal imaging, making a single device capable of comprehensive ophthalmic assessment from cornea to choroid.

Intraoperative OCT and AR Integration: The Highest-Value Near-Term Application

Among all application domains in this dataset, intraoperative OCT filings — spanning cataract surgery, glaucoma surgery, vitreoretinal procedures, and intraocular lens adjustment — represent the largest and most commercially active cluster. The strategic rationale is clear: real-time 3D tissue visualization during active surgery reduces procedural uncertainty and enables closed-loop instrument guidance that was previously impossible with conventional surgical microscopes.

“Intraoperative OCT filings — spanning cataract, glaucoma, vitreoretinal, and IOL adjustment applications — represent the largest and most commercially active cluster in the OCT patent landscape. R&D teams and IP strategists should monitor Alcon’s comprehensive portfolio for freedom-to-operate implications.”

The Suzhou Institute of Biomedical Engineering and Technology (Chinese Academy of Sciences) filed a 2023 JP patent fusing 2D microscope video and 3D OCT volumes using synchronized guide illumination, enabling real-time augmented reality overlay during microsurgery. Bioptigen’s 2019 EP filing describes a complete procedural OCT workflow — subject orientation, structural baseline construction, clinical parameter computation, and iterative plan modification — anchored by intraoperative OCT feedback. These filings reflect the maturation of MIOCT (microscope-integrated OCT) from research prototype to clinical workflow standard.

Novartis AG’s 2020 JP tracking system for surgical OCT enables beam scanner redirection to follow intraocular instruments in real time — a capability that becomes essential when instruments move faster than a fixed OCT scan window can capture. Alcon’s 2025 JP filing on IOL adjustment systems extends intraoperative OCT to post-implant refractive adjustment, meaning OCT guidance now covers the entire surgical episode from pre-operative planning through lens implantation to final refractive verification.

Glaucoma surgery represents a distinct intraoperative OCT sub-cluster. Individual inventor Michael S. Berlin holds approximately 6–7 records for OCT-guided glaucoma surgery systems across JP and KR jurisdictions, targeting trabecular meshwork and Schlemm’s canal access — anatomical structures whose precise localization is critical for minimally invasive glaucoma surgery (MIGS) procedures. According to WHO, glaucoma is the leading cause of irreversible blindness worldwide, making precise surgical guidance tools a high-priority clinical need.

AI-Enhanced OCT Image Processing: Approaching IP Saturation

AI and machine learning applications to OCT data represent the fastest-growing technical sub-domain in the mid-to-late stage of the dataset, with multiple assignees filing foundational patents on noise reduction, super-resolution, disease prediction, and tissue feature extraction. The strategic implication is significant: this sub-domain is approaching IP saturation, meaning that differentiating new filings will need to claim specific model architectures, training dataset constructions, or clinical-task-specific outputs rather than general AI application to OCT data.

The Medical University of Vienna’s 2024 EP patent applies a prediction model to retinal OCT data to generate prospective tissue feature parameters — enabling predictive monitoring of disease progression rather than just current-state diagnosis. This filing is the most recent of four Vienna records spanning WO (2016), US (2018), and EP (2020, 2024), representing one of the most geographically distributed single-assignee AI OCT portfolios in the dataset. Research published by Nature has documented the clinical potential of deep learning models for retinal disease prediction from OCT scans, providing scientific context for this IP activity.

Nidek Co., Ltd.’s 2020 JP patent trains a machine learning model on addition-averaged multi-frame images to generate high-quality target images from lower-quality base inputs, suppressing speckle noise — a persistent image quality challenge in OCT that degrades diagnostic confidence. The Ningbo Institute of Industrial Technology (Chinese Academy of Sciences) applied unpaired deep learning to translate wide-area low-resolution OCTA sub-images to high-resolution equivalents in a 2020 CN filing, solving the paired training data scarcity problem that limits supervised super-resolution approaches in medical imaging.

Intravascular OCT (IVOCT) for coronary imaging represents a distinct AI application cluster in Korean filings. Keimyung University’s 2021 KR AI-based computer-aided diagnosis system performs automatic vessel lumen detection, shape feature extraction, and normal/abnormal lumen classification. A 2025 KR filing uses AI models to identify bifurcation points in intravascular OCT image sequences — a capability directly relevant to coronary intervention planning. According to WHO, cardiovascular disease remains the leading cause of death globally, underscoring the clinical stakes of accurate intravascular imaging.

Geographic and Assignee Landscape: Who Holds the Key Positions

Japan dominates the OCT patent dataset by filing volume, reflecting the strategy of major ophthalmic and precision optics companies — including Alcon, Novartis, Carl Zeiss Meditec, Nidek, Topcon, and Canon — filing in Japan as a key commercial market. China is the second most represented jurisdiction, with filings from Carl Zeiss Meditec, the Chinese Academy of Sciences (Suzhou and Ningbo), Nanyang Technological University, the University of Southern California, and domestic players such as Shenzhen Sierdon Technology. Korea features strongly in surgical guidance (Michael S. Berlin’s glaucoma portfolio) and AI-based intravascular OCT (Keimyung University). European jurisdictions (EP, ES, IT) host filings from Alcon Inc., Bioptigen, Novartis, DAMAE Medical (France), Politecnico di Milano, and CenterVue.

Innovation concentration is relatively high in this dataset — the top five assignee groups account for the majority of retrieved records — but a long tail of academic and specialty assignees (EPFL, Keimyung University, Zhejiang University, University of Southern California, University of Kent, DAMAE Medical, Optos PLC, Toward Pi Beijing) reflects broad global research activity. This pattern is consistent with the broader medtech patent landscape documented by WIPO, where a small number of large commercial assignees dominate by volume while academic institutions establish foundational positions in emerging sub-domains.

Nanyang Technological University’s 2024 CN filing on a dispersive-element-based wide-field OCT system explicitly demonstrates in vivo human skin OCTA imaging — generating wide-field vascular network maps of the skin — extending the OCT application space beyond ophthalmology into dermatology. DAMAE Medical’s 2020 ES filing on optical tomography apparatus and procedure represents European commercial activity in non-ophthalmic OCT applications. For IP strategists, the PatSnap IP intelligence platform provides freedom-to-operate analysis across these multi-jurisdictional portfolios.

Emerging Directions: Robotics, Home Use, and Tissue Velocity Analysis

The most recent filings in the dataset (2024–2026) reveal five forward-looking trajectories that define where OCT innovation is headed over the next patent cycle. Of these, OCT-guided robotics represents the highest-growth white space — only a small number of filings explicitly address closed-loop OCT-to-robot coordinate mapping, meaning early patent positions in this domain may carry significant strategic value.

Alcon’s 2025 JP filing on OCT-guided robotic ophthalmic procedures uses multi-galvanometer absolute and incremental encoder data to map OCT-derived tissue positions into the robot’s 3D coordinate system, enabling submillimeter-precision autonomous or assisted instrument placement. Toward Pi (Beijing) Medical Technology’s 2026 KR filing pursues real-time 3D OCT navigation tied to galvanometer scanners — the most recent filing in the entire dataset and a signal of accelerating commercial interest in closed-loop robotic OCT from Chinese medtech innovators.

The second emerging direction is integrated OCT and stereoscopic volumetric visualization. Alcon’s 2025 EP filing integrates an OCT module and stereoscopic visualization camera in a single head unit, registering volumetric OCT and stereo camera data to produce a composite shared view of the surgical target — eliminating the traditional separation between surgical visualization and depth imaging. A companion calibration system filed in CN (2025) addresses the registration accuracy requirements that make this integration clinically usable.

Optos PLC’s 2025–2026 JP filings introduce per-voxel tissue velocity indexing from phase information in sequential OCT image sets — a functional extension of structural OCT toward quantitative biomechanics. This approach moves beyond anatomical imaging into physiological measurement, potentially enabling new biomarkers for retinal disease monitoring. Optos’ separate 2026 JP filing on scleral promontory visibility in anterior segment OCT targets automated scleral spur localization for geometric angle measurement — directly relevant to glaucoma screening workflows.

Home-based and patient-operated OCT represents the fifth emerging direction. Acucela Inc.’s dual JP filings (2023 and 2025) describe compact, drop-resistant, self-administered OCT devices for at-home retinal thickness monitoring by patients without clinical assistance. Doheny Eye Institute’s 2011 EP/US filings prefigured this direction over a decade earlier. The barriers to widespread adoption are not primarily IP-related: regulatory pathway, miniaturization cost, and patient adherence — not patent landscape density — are the primary constraints, making this a domain where non-IP strategic investments may be as important as filing strategy. The PatSnap Insights blog covers regulatory and commercial strategy across medtech verticals including point-of-care diagnostics.

“With Acucela and Doheny Eye Institute both filing patient-operated OCT systems, the transition from clinic-bound to patient-administered monitoring is technically documented. Regulatory pathway, miniaturization cost, and patient adherence — not IP landscape density — are the primary barriers to entry.”